What Are Wall Street Analysts' Target Price for Abbvie Stock?

Headquartered in North Chicago, AbbVie Inc. (ABBV)  is a prominent global pharmaceutical leader with a market cap of $334.3 billion. The company excels in immunology with treatments like Humira, Skyrizi, and Rinvoq and in oncology with Imbruvica and Venclexta.

Shares of the pharma giant have surpassed the broader market over the past year. While ABBV stock has surged 26.7% over this time frame, the S&P 500 Index ($SPX) has rallied by 18.5%. In 2024, the stock rose 22.2%, compared to SPX’s 12.1% return on a YTD basis.